Biogen
NEWS
A new report highlights some concerns about the long-term commercial viability of game-changing gene therapies that can radically transform the lives of patients.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
PTC Therapeutics presented updated interim clinical data from Part 1 of its FIREFISH clinical trial of risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy.
AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Alkermes, received a $50 million milestone payment from Biogen. The payment occurred after Biogen reviewed preliminary gastrointestinal tolerability data from an ongoing Phase III clinical trial for MS.
JOBS
IN THE PRESS